Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) gapped down before the market opened on Monday following a dissappointing earnings announcement. The stock had previously closed at $9.21, but opened at $8.87. BioCryst Pharmaceuticals shares last traded at $8.06, with a volume of 1,452,227 shares trading hands.
The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million for the quarter, compared to analysts' expectations of $126.64 million. The company's revenue for the quarter was up 40.8% on a year-over-year basis. During the same period last year, the company posted $0.28 earnings per share.
Wall Street Analyst Weigh In
A number of research analysts have weighed in on the company. Needham & Company LLC upped their target price on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a "buy" rating in a report on Monday, January 13th. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday. Evercore ISI raised their price objective on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an "outperform" rating in a research report on Monday, January 13th. Royal Bank of Canada restated an "outperform" rating and set a $11.00 target price (up previously from $10.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday. Finally, Wedbush initiated coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday. They issued an "outperform" rating and a $15.00 price target for the company. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $15.57.
Check Out Our Latest Stock Analysis on BioCryst Pharmaceuticals
Institutional Trading of BioCryst Pharmaceuticals
Several institutional investors have recently bought and sold shares of BCRX. Creative Planning lifted its stake in shares of BioCryst Pharmaceuticals by 5.9% in the third quarter. Creative Planning now owns 49,347 shares of the biotechnology company's stock worth $375,000 after buying an additional 2,734 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in BioCryst Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company's stock worth $57,000 after acquiring an additional 1,322 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in BioCryst Pharmaceuticals by 44.5% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 17,344 shares of the biotechnology company's stock valued at $132,000 after acquiring an additional 5,340 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in BioCryst Pharmaceuticals by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,791 shares of the biotechnology company's stock valued at $302,000 after purchasing an additional 15,544 shares during the last quarter. Finally, Rice Hall James & Associates LLC boosted its stake in BioCryst Pharmaceuticals by 4.0% during the 3rd quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company's stock valued at $16,444,000 after purchasing an additional 84,102 shares during the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.
BioCryst Pharmaceuticals Stock Performance
The stock has a fifty day simple moving average of $8.09 and a 200 day simple moving average of $7.85. The firm has a market cap of $1.75 billion, a P/E ratio of -13.89 and a beta of 1.75.
BioCryst Pharmaceuticals Company Profile
(
Get Free Report)
BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
See Also
Before you consider BioCryst Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioCryst Pharmaceuticals wasn't on the list.
While BioCryst Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
